Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Same Day vs Next Day Pegfilgrastim with TAC in Breast Cancer
NCT00115414Phase 2Completed
- Sponsor
- Amgen
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of pegfilgrastim in neutropenia (2 arms), sponsored by Amgen. Primary endpoint: Duration of Grade 4 Neutropenia. Status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT00115414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115414.